A Study to Characterize LY3314814 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of LY3314814 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Lanabecestat (Primary) ; Donepezil; Midazolam; Midazolam; Simvastatin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 23 Apr 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 23 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.